Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Plasmodium falciparum resistance against artemisinins has been confirmed in South-East Asia and it is expressed phenotypically as a slow rate of parasite clearance. Nonetheless, it is not known whether the problem exist in Tanzania. This study assessed parasite clearance time and time to recurrent infection following treatment with Artemether/Lumefantrine (AL) among children with uncomplicated malaria.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Muhimbili University of Health and Allied Sciences
• Collaborator: Karolinska Institutet
• Treatments: Artemether; Artemether-lumefantrine combination; Artemether, Lumefantrine Drug Combination; Artemisinins; Lumefantrine

Criteria

Inclusion Criteria:

• Age 6-120 months

• Presence of asexual P. falciparum parasitaemia of 2000-200 000/μL

• No general danger signs or severe malaria present

• Hemoglobin ≥5 g/dL

• History of fever within 24 hours or axillary temperature ≥ 37.5 degree Celsius

• No other cause of fever is detectable

• No severe malnutrition

• Guardian/patient has consented

Exclusion Criteria:

• general danger signs or signs of severe falciparum malaria

• severe malnutrition

• febrile condition due to diseases other than malaria

• regular medication which might interfere with antimalarial pharmacokinetics

• contraindications to any medicine being used